Science and Technology
publicado em 06/08/2013 às 09h58:00
   Dê o seu voto:

The biologic drug bevacizumab is used in fighting cancer and age-related macular degeneration

font size

Some pieces of information on this page may have been automatically translated. Makernews is not responsible for the irregularities resulting from these translations. When in doubt,      consult the original text.

Foto: Divulgação/AENPR
Delegation visit to Paraná Brazil Biocad to tune in Russia cooperation agreement.
  « Previous
next »  
Delegation visit to Paraná Brazil Biocad to tune in Russia cooperation agreement.

The Institute of Technology of Paraná (Tecpar) will produce biologic drug Avastin, the latest generation for the fight against cancer and macular degeneration (vision loss) relative to age. The product uses the active ingredient of Avastin, Roche, whose patent expired in 2012. The production of the drug in Paraná was completed during a mission trip to Russia Tecpar, in order to finalize the details of the cooperation agreement signed between the institute and Biocad Brazil.

The meetings between the two parties took place in two cities of Russia - St. Petersburg and Moscow - with visits to the Biocad a Russian biotech company, whose focus is research, development, production, innovation, and marketing of pharmaceuticals of biological origin. These contacts served to start a schedule of technology transfer, from staff training to achieve production in the laboratory Tecpar, to be installed in the technology park of Maringa.

The Tecpar now passes to a new stage in its history. Known and respected for the development and production of biopharmaceuticals, now also part of the list of producers of biological art. It is a great challenge that lies ahead, helping to improve public health in the country says Julio Felix, CEO of Tecpar, who joined the mission to Russia Paraná.

The partnership between Tecpar Biocad and Brazil had already been formalized in a meeting at the Ministry of Health in Brasilia in June. On occasion, officers Tecpar presented to the Secretary of Science, Technology and the Ministry of Health, Carlos Gadelha, elaborate design among partners, as demand federal agency itself, from the first contacts for presentation to the possibility of a job set between the parties, which follows the model of Productive Development Partnership (PDP).

The Partnership for Productive Development aims to reduce the development time of new products, using technology transfer of the production process of strategic medicines that are already developed by private enterprise. The deadline for a PDP is five years, during which the product must have been registered in Brazil while all its stages of production should also be being held in the country.

By the official deadline that compromise between Tecpar Biocad and in 2017 the first products of the new laboratory to be installed will be delivered.

   Palavras-chave:   Avastin    The cancer drug    Tecpar    Roche    Avastin    Biocad    Julio Felix    Health   
  • Share this pageShare this page
  • Share this pageCorrect
  • ShareShare
  • AlertAlert
Reduced link: 
  • You are recommending this story:
  • Fill in the following form to send your recommendation to your friend:

  • You are suggesting a correction for this story:

Receba notícias do iSaúde no seu e-mail de acordo com os assuntos de seu interesse.
Seu nome:
Seu email:
Desejo receber um alerta com estes assuntos:
Avastin    the cancer drug    Tecpar    Roche    Avastin    Biocad    Julio Felix    health   
Leave your comment
(Required fields are marked with an *)

(Your email address will never be published or shared.)

Enter the letters and numbers below and click in the button "send"

  • Twitter iSaúde
Informe Saúde printed version

Recommend the portal
Close [X]
  • You are recommending this story:
  • Fill in the following form to send your recommendation to your friend:

RSS news from the portal  iSaú
Get the newsletter of the portal  iSaú
Recommend the portal iSaú
News from  iSaú in your blog or website.
Get news on the subject of your interest.
© 2000-2011 Todos os direitos reservados.